Allarity Therapeutics’ (ALLR) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of Allarity Therapeutics (NASDAQ:ALLR) in a research report released on Friday,Weiss Ratings reports.

Other equities research analysts have also issued reports about the stock. Ascendiant Capital Markets lifted their price target on shares of Allarity Therapeutics from $9.00 to $9.25 and gave the company a “buy” rating in a research note on Friday, September 26th. Wall Street Zen raised Allarity Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $9.25.

Allarity Therapeutics Stock Performance

NASDAQ ALLR opened at $1.39 on Friday. Allarity Therapeutics has a 52 week low of $0.61 and a 52 week high of $2.35. The stock’s 50 day moving average price is $1.52 and its two-hundred day moving average price is $1.17. The stock has a market capitalization of $20.19 million, a price-to-earnings ratio of -0.17 and a beta of 0.22.

Allarity Therapeutics (NASDAQ:ALLR) last posted its quarterly earnings data on Friday, August 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06. On average, equities research analysts forecast that Allarity Therapeutics will post -78.08 EPS for the current year.

Institutional Trading of Allarity Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in shares of Allarity Therapeutics during the 2nd quarter worth approximately $27,000. Geode Capital Management LLC raised its stake in Allarity Therapeutics by 49.3% in the 2nd quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after acquiring an additional 16,729 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Allarity Therapeutics during the 2nd quarter valued at $51,000. Institutional investors own 11.53% of the company’s stock.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.